论文部分内容阅读
最近,据美国临床肿瘤学会会议报道,临床试验结果表明聚乙二醇化白细胞介素2(PEG IL-2)有较长的半衰期,毒性亦较无PEG的IL-2低,并且在癌症患者身上仍显示出抗肿瘤活性。在美国加利福尼亚大学Davis医学中心的Meyers等所进行的Ⅰ期试验中,31例患者经周围静脉输注15分钟,接受了18万～430万IU的PEG IL-2。注入后24～48小时发现嗜酸粒细胞和淋巴细胞增多。在18万～170万IU剂量范围内,PEG IL-2的体内半衰期比无PEG的IL-2大10倍:α半衰期为150分钟,β半衰期为720分钟。
Recently, according to the American Society of Clinical Oncology meeting, clinical trials showed that PEGylated interleukin 2 (PEG IL-2) has a longer half-life and is less toxic than non-PEG-containing IL-2 and is found in cancer patients Still show antitumor activity. In a Phase I trial conducted by Meyers et al. At the Davis Medical Center at the University of California, 31 patients received between 180,000 and 4.3 million IU of PEG IL-2 over 15 minutes of peripheral venous infusion. Eosinophils and lymphocytes were found to be increased 24 to 48 hours after injection. The in vivo half-life of PEG IL-2 was 10-fold greater than that of PEG-free IL-2 at a dose range of 180,000 to 1.7 million IU: alpha half-life of 150 minutes and beta half-life of 720 minutes.